SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Regeneron Pharmaceuticals, Inc. 
 NY
  SEC # 872589


        
    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

400  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
4/25/24New Filing!  DEF 14A1Additional Compensation Information
1Advisory Vote on Compensation of Named Executive Officers (Say-on-Pay)
5/2/24New Filing!  10-Q1And
5/4/2310-Q1And 20
2/5/2410-K1And 202
1And Issuer Purchases of Equity Securities
4/25/24New Filing!  DEF 14A1Annual Cash Incentives
1Annual Equity Awards
1Appendix A -- Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures
1Appendix B -- Supplemental Information Regarding Outstanding Performance Restricted Stock Unit Awards
1Audit Committee Report
1Audit Matters
1Back to Contents
1Base Salaries
1Board and Committee Self-Assessments
1Board Committees
1Board Diversity
1Board Governance
4/21/23DEF 14A1Board Leadership Structure
4/25/24New Filing!  DEF 14A1Board Leadership Structure; Responsibilities of Lead Independent Director
1Board Meetings and Attendance of Directors
1Board of Directors
1Board Oversight of Risk and Key Pricing Decisions
1Board Snapshot
1Board Structure
2/5/2410-K1Business
4/25/24New Filing!  DEF 14A1Capital Structure
1Certain Relationships and Related Transactions
2/5/2410-K1Certain Relationships and Related Transactions, and Director Independence
1Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
4/25/24New Filing!  DEF 14A1Code of Ethics
1Company, The
1Compensation and Governance Practices Designed to Drive Long-Term Performance
1Compensation Committee
1Compensation Committee Interlocks and Insider Participation
1Compensation Committee Report
1Compensation Dashboard
1Compensation Discussion and Analysis
1Compensation of Directors
1Compensation Processes
1Compensation Program Objectives
1Compensation Program Overview
1Compensation-Related Matters
1Components of Executive Pay: What We Pay and Why We Pay It
5/2/24New Filing!  10-Q1Condensed Consolidated Balance Sheets
11/2/2310-Q1Condensed Consolidated Balance Sheets as of
8/3/2310-Q1Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022
5/4/2310-Q1Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Cash Flows
11/2/2310-Q1Condensed Consolidated Statements of Cash Flows for the
8/3/2310-Q1Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Operations and Comprehensive Income
5/4/2310-Q1Condensed Consolidated Statements of Operations and Comprehensive Income for the Three
11/2/2310-Q1Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and
8/3/2310-Q1Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Stockholders' Equity
5/4/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the Three
11/2/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the Three and
8/3/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2023 and 2022
2/5/2410-K1Consolidated Balance Sheets as of December 31, 202
1Consolidated Statements of Cash Flows for the Years Ended December 31, 202
1Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 202
1Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 202
1Contents
5/2/24New Filing!  10-Q1Controls and Procedures
4/25/24New Filing!  DEF 14A1Corporate Governance
1Corporate Governance Aspects of the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan
1Corporate Responsibility
2/5/2410-K1Cybersecurity
4/25/24New Filing!  DEF 14A1Director Independence
1Director Onboarding
1Director Refreshment Philosophy
2/5/2410-K1Directors, Executive Officers and Corporate Governance
1Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
4/25/24New Filing!  DEF 14A1Election of Directors
1Equity Compensation Information
1Equity Compensation Plan Information
2/5/2410-K1Executive Compensation
4/25/24New Filing!  DEF 14A1Executive Compensation Processes and Procedures; Role of Compensation Consultants
1Executive Compensation Program Overview
1Executive Officers of the Company
1Executive Summary
5/2/24New Filing!  10-Q1Exhibits
2/5/2410-K1Exhibits and Financial Statement Schedules
5/2/24New Filing!  10-Q1Financial Information
1Financial Statements (unaudited)
2/5/2410-K1Financial Statements and Supplementary Data
1Form 10-K Summary
4/25/24New Filing!  DEF 14A1General Information about the Meeting and Other Matters
1How Our Pay Program Works
1Independent Compensation Consultant
1Information about Fees Paid to Independent Registered Public Accounting Firm
1Introduction
5/2/24New Filing!  10-Q1Item 1
2/5/2410-K1Item 10
1Item 11
1Item 12
1Item 13
1Item 14
1Item 15
1Item 16
5/2/24New Filing!  10-Q1Item 1A
2/5/2410-K1Item 1B
5/2/24New Filing!  10-Q1Item 2
1Item 3
1Item 4
1Item 5
1Item 6
2/5/2410-K1Item 7
1Item 7A
1Item 8
1Item 9
1Item 9A
1Item 9B
1Item 9C
4/25/24New Filing!  DEF 14A1Key Equity Metrics
1Key Governance Features
5/2/24New Filing!  10-Q1Legal Proceedings
4/25/24New Filing!  DEF 14A1Longstanding Commitment to Shareholder Engagement
1Management
5/2/24New Filing!  10-Q1Management's Discussion and Analysis of Financial Condition and Results of Operations
5/4/2310-Q1March
1March 31
2/5/2410-K1Market for Registrant's Common Equity, Related Stockholder Matters
4/25/24New Filing!  DEF 14A1Meet the Board
2/5/2410-K1Mine Safety Disclosures
11/2/2310-Q1Months Ended
4/25/24New Filing!  DEF 14A1New Board Leadership Structure
11/2/2310-Q1Nine
4/25/24New Filing!  DEF 14A1Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements
1Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures
5/2/24New Filing!  10-Q1Notes to Condensed Consolidated Financial Statements
2/5/2410-K1Notes to Consolidated Financial Statements
4/25/24New Filing!  DEF 14A1Other
5/2/24New Filing!  10-Q1Other Information
4/25/24New Filing!  DEF 14A1Other Matters
1Our Corporate Culture and Pay Philosophy
4/21/23DEF 14A1Outstanding Equity Awards at 2022 Fiscal Year-End
4/25/24New Filing!  DEF 14A1Outstanding Equity Awards at 2023 Fiscal Year-End
1Overview
5/2/24New Filing!  10-Q1Part I
1Part Ii
2/5/2410-K1Part Iii
1Part Iv
4/25/24New Filing!  DEF 14A1Pay Ratio
1Pay Versus Performance
1Peer Data
1Perquisites and Personal Benefits
1Post-Employment Compensation
1Potential Severance Payments
2/5/2410-K1Power of Attorney (included on the signature page of this Annual Report on Form 10-K)
1Principal Accountant Fees and Services
4/25/24New Filing!  DEF 14A1Procedures Relating to Nominees; Board Succession Planning
2/5/2410-K1Properties
4/25/24New Filing!  DEF 14A1Proposal No. 1
4/21/23DEF 14A1Proposal No. 1 Election of Directors
4/25/24New Filing!  DEF 14A1Proposal No. 2
4/21/23DEF 14A1Proposal No. 2 Ratification of Appointment of Independent Registered Public Accounting Firm
4/25/24New Filing!  DEF 14A1Proposal No. 3
4/21/23DEF 14A1Proposal No. 3 Advisory Vote on Compensation of Named Executive Officers (Say-On-Pay)
4/25/24New Filing!  DEF 14A1Proposal No. 4
4/21/23DEF 14A1Proposal No. 4 Advisory Vote on the Frequency of Future Say-On-Pay Votes (Say-On-Frequency)
1Proposal No. 5 Non-Binding Shareholder Proposal Requesting Report on A Process by Which Access to Medicine Is Considered in Matters Related to Protecting Intellectual Property
4/25/24New Filing!  DEF 14A1Proxy Dashboard
1Proxy Highlights
1Public Policy Engagement
5/2/24New Filing!  10-Q1Quantitative and Qualitative Disclosures About Market Risk
4/25/24New Filing!  DEF 14A1Ratification of Appointment of Independent Registered Public Accounting Firm
1Recent Director Refreshment
2/5/2410-K1Report of Independent Registered Public Accounting Firm (PCAOB ID
1Reserved
4/25/24New Filing!  DEF 14A1Review, Approval, or Ratification of Transactions with Related Persons
1Risk Assessment
5/2/24New Filing!  10-Q1Risk Factors
4/25/24New Filing!  DEF 14A1Risk Oversight
1Security Ownership of Certain Beneficial Owners and Management
2/5/2410-K1Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
11/2/2310-Q1September
4/25/24New Filing!  DEF 14A1Shareholder Communications
1Shareholder Engagement
1Shareholder Engagement and Feedback
1Shareholder Engagement Philosophy and Board Responsiveness
4/21/23DEF 14A1Shareholder Input and Outreach and the 2022 Say-on-Pay Vote Result
4/25/24New Filing!  DEF 14A1Shareholder Input and Outreach and the 2023 Say-on-Pay Vote Result
1Shareholder Right to Call Special Shareholder Meeting
1Shareholders
5/2/24New Filing!  10-Q1Signature Page
4/25/24New Filing!  DEF 14A1Stock Ownership Guidelines
1Succession Planning and Talent Development Process
1Supplemental Information Regarding Outstanding Performance Restricted Stock Unit Awards
2/5/2410-K1Table
1Table of
5/2/24New Filing!  10-Q1Table of Contents
4/25/24New Filing!  DEF 14A1Tax Implications
2/5/2410-K1Tem 1C
4/25/24New Filing!  DEF 14A1The Company
5/4/2310-Q1Three
4/25/24New Filing!  DEF 14A1Transactions with Related Persons
5/2/24New Filing!  10-Q1Unregistered Sales of Equity Securities
8/3/2310-Q1Unregistered Sales of Equity Securities and Use of Proceeds
11/2/2310-Q1Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
2/5/2410-K1Unresolved Staff Comments
5/2/24New Filing!  10-Q1Use of Proceeds
4/25/24New Filing!  DEF 14A1Users' Guide
1100
1101
1102
1103
1104
1106
4/21/23DEF 14A1110
4/25/24New Filing!  DEF 14A1112
1115
2/5/2410-K1202
4/21/23DEF 14A12022 Business Highlights
12022 Compensation Highlights
12022 Executive Compensation Tables
12022 Grants of Plan-Based Awards
12022 Option Exercises and Stock Vested
12022 Summary Compensation Table
4/25/24New Filing!  DEF 14A12023 Business Highlights
12023 Compensation Highlights
12023 Executive Compensation Tables
12023 Grants of Plan-Based Awards
12023 Option Exercises and Stock Vested
12023 Summary Compensation Table
11/2/2310-Q130, 2023 and 2022
130, 2023 and December 31, 2022

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 5, 7:56:22.3pm ET